Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000169608 | SCV000221130 | likely pathogenic | Neuronal ceroid lipofuscinosis 2 | 2015-02-11 | criteria provided, single submitter | literature only | |
Gene |
RCV000189791 | SCV000243439 | pathogenic | not provided | 2012-04-19 | criteria provided, single submitter | clinical testing | p.Trp460Stop (TGG>TAG): c.1379 G>A in exon 11 of the TPP1 gene (NM_000391.3) The Trp460Stop nonsense mutation in the TPP1 gene has been reported previously in association with neuronal ceroid lipofuscinosis (NCL) (Sleat et al., 1997; Zhong et al., 2000). This mutation is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The variant is found in CHILD-EPI panel(s). |
Invitae | RCV000189791 | SCV001589888 | pathogenic | not provided | 2021-10-27 | criteria provided, single submitter | clinical testing | This premature translational stop signal has been observed in individual(s) with late-infantile neuronal ceroid lipofuscinosis (PMID: 11339651). For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. ClinVar contains an entry for this variant (Variation ID: 189179). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Trp460*) in the TPP1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TPP1 are known to be pathogenic (PMID: 10330339). |
Fulgent Genetics, |
RCV002498846 | SCV002809603 | pathogenic | Neuronal ceroid lipofuscinosis 2; Autosomal recessive spinocerebellar ataxia 7 | 2022-04-04 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000169608 | SCV002094810 | pathogenic | Neuronal ceroid lipofuscinosis 2 | 2021-09-24 | no assertion criteria provided | clinical testing |